Many clinical trial results not shared, creating 'blind spot'

Less than 40% of the results of clinical trials conducted at leading academic medical centers were shared within two years of completion, Yale School of Medicine researchers report in a new study published in the current issue of the British Medical Journal.

"Not only was performance poor, but there was significant variation across the academic medical centers we studied," said Dr. Nihar Desai, assistant professor of medicine, section of cardiology at Yale School of Medicine and a researcher at the Yale Center for Outcomes Research and Evaluation.

Desai said randomized clinical trials are the gold standard in terms of testing the efficacy and safety of drugs, devices, and treatment strategies, so disseminating the results is of vital importance.

"Researchers also have an ethical responsibility to the patients enrolled in the study to make the results available," he said. "Providers and patients will never be able to make evidence-based health care decisions if the data is not in the public domain. In addition, future research cannot benefit from what other researchers have already done if results are not reported and/or published in a timely fashion."

Desai and his co-authors previously studied the rates of results reporting and publication of clinical trials sponsored by the National Institutes of Health and by pharmaceutical companies. They decided to extend that prior work by looking at the dissemination of clinical trial results across leading academic institutions. The team reviewed over 4,300 clinical trials and examined how many were published or had results reported on ClinicalTrials.gov within 24 months of the studies' completion.

The team saw a three-fold variation in performance, with some institutions disseminating 16% of their completed clinical research, while others disseminated 55%.

"This is yet another blind spot in the clinical research enterprise, and we hope our findings will serve as a call to action," said Desai. "Academic medical centers are uniquely positioned to lead this effort. They are dedicated to generating knowledge to improve health and health care. We hope our study will lead to a renewed commitment to our professional values and the mission of academic centers to not only conduct rigorous scientific investigation, but to share the results in a timely and transparent fashion."

Other authors on the study included first author Ruijun Chen, Joseph S. Ross, Weiwei Zhang, Katherine H. Chau, Brian Wayda, Karthik Murugiah, Daniel L. Lu, Amit Mittal, and senior author Harlan M. Krumholz.

Most Popular Now

Meditation, yoga and vegetarian diet linked to dec…

In a novel controlled clinical trial, participants in a six-day Ayurvedic-based well-being program that featured a vegetarian diet, meditation, yoga and massages experien...

Read more

Abbott to sell Abbott Medical Optics to Johnson …

Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. Abbott's vision bus...

Read more

Caffeine and its analogues revert memory deficits …

A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in ...

Read more

Amgen obtains global development and commercial ri…

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG...

Read more

Roche ranked most sustainable healthcare company i…

For the eighth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life...

Read more

10th European Medical Information and Communicatio…

29 - 30 November 2016, Berlin, Germany The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical in...

Read more

Study shows how Chinese medicine kills cancer cell…

Researchers at the University of Adelaide have shown how a complex mix of plant compounds derived from ancient clinical practice in China - a Traditional Chinese Medicine...

Read more

Benralizumab phase III trials show positive result…

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care...

Read more

Pfizer launches new "Moodivator" app to …

Pfizer Inc. (NYSE:PFE) has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most ...

Read more

Antibody reduces harmful brain amyloid plaques in …

Although the causes of Alzheimer's disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons...

Read more

Nano-lipid particles from edible ginger could impr…

Edible ginger-derived nano-lipids created from a specific population of ginger nanoparticles show promise for effectively targeting and delivering chemotherapeutic drugs ...

Read more

Special T cells that target solid tumors offer pot…

Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell m...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]